-
Clinical trials of AbbVie IL-23 inhibitors Phase 3 were positive
Time of Update: 2021-01-14
Risankizumab (SKYRIZI®) Phase 3 Results Managers in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients.
-
CRSwNP competition intensifies GSK's IL-5 single anti-Nucala new adaptive application to be accepted by the FDA
Time of Update: 2021-01-01
combined with multiple inflammation (EGPA). this time, Nucala's application for treatment of CRSwNP's adaptation is based on the positive results of its key Phase III study SYNAPSE. The study, designed in a randomized, double-blind
-
IL-6R single anti-Enspryng approved in Taiwan, China!
Time of Update: 2020-12-28
system that mainly damages the optic nerve and spinal cord, leading to blindness, muscle weakness and paralysis. In two key Phase III clinical studies, Enspryng, as a monotherapy and as an additional therapy for baseline immunosuppressant
-
Blood: IL-18 mediates the occurrence of sickle cell cardiomyopathy and cytocardiac titration
Time of Update: 2020-12-24
expression of the IL18 gene was enhanced in patients with myocardial fibrosis or QTc-enhanced SCD, and QTc was closely related to plasma IL-18 levels.
-
New drug for psoriasis arthritis (PsA)! The Johnson and Johnson IL-23 inhibitor Tremfya (Tenoya ®
Time of Update: 2020-12-21
/> In 2 studies, patients were randomly assigned to Tremfya 100mg every 4 weeks (Q4W) or every 8 weeks (Q8W) for 52 weeks, and patients receiving placebo were treated with Tremfya Q4W at the 24th week of treatment until week 52. 24-week results
-
Kangfang bio-targeted IL-4R new drug approved clinically in the United States
Time of Update: 2020-12-13
, low penetration and excellent clinical performance of IL-4R monoantials are expected to meet the unfinished needs of patients worldwide, according to the press release.
-
The study found the interaction between IL-10 and COMT gene polymorphism in cognitive function in patients with schizophrenia
Time of Update: 2020-12-11
in patients with schizophrenia and healthy populations. , Wang Jies, an assistant researcher in the Mental Health Key Laboratory of the Institute of Psychology of the Chinese Academy of Sciences, conducted a targeted study. the study recruited 244
-
IL-23 inhibitor Tremfya has been recommended by the European Union CHMP approval domestic market!
Time of Update: 2020-11-06
. Tremfya is a monoclonal antibody that selectively binds to p19 sub-base of leukocyte mesokine-23 (IL-23) and inhibits its interaction with IL-23 receptors. IL-23 is a naturally occurring cytokine and an important driver
-
with anti-IL-17 monoantigen Bimekizumab was better than TNF monoantigen
Time of Update: 2020-11-06
results showed that at the 16th week of treatment, 86.2% of patients treated with bimekizumab had almost skin loss (PASI 90), while 47.2% of patients treated with Adamo monoantigen (p .lt;0.001).
-
New drug for psoriasis! The Johnson il-23 inhibitor Tremfya (Tenoya ®) has been used continuously
Time of Update: 2020-11-02
of new open label expansion data, showing that Tremfya treatment showed a high rate of skin loss removal, treatment in the last 5 years found no new safety signals. noted that this is the first clinical study to evaluate an IL-23 inhibitor
-
NIH initiated clinical trials to test IL-23 antibodies;
Time of Update: 2020-11-02
the clinical trial will initially test the effectiveness of the IL-23 antibody Risankizumab (commodity name Skyrizi) developed jointly by Boehringer Ingelheim and AbbVie to treat hospitalized COVID-19 patients compared to placebo and redsiwe.
-
New drug for psoriasis arthritis (PsA)! Johnson il-23 inhibitor Tremfya (Tenoya ®) recommended by the European Union CHMP approval, China has been listed!
Time of Update: 2020-11-01
in the European Union, Tremfya was first approved in November 2017 to treat adult patients with moderate to severe plaque psoriasis suitable for systemic therapy.
-
Phase III data prove that IL-23 monoantigen TREMFYA can maintain skin removal rate in patients with plaque psoriasis for 5 consecutive years.
Time of Update: 2020-10-28
monoclonal antibody of all-human-targeted interleukin (IL)-23, which selectively binds to the p19 sub-base of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is an important cause of inflammatory diseases such as psoriasis.
-
Determination of the biological activity of lecytosin-2 (IL-2).
Time of Update: 2020-10-27
1. 1640 cultured liquid (full), IL-2 standard , IL-2 sample to be tested, CTLL-2 cell strain, MTT solution (5mg/ml), 10% SDS 2.
-
Lilly and Johnson and Johnson announce the latest clinical results of IL-23 inhibitors for Crohn's disease!
Time of Update: 2020-10-23
the safety and effectiveness of multiple dosage regimens and two dosing regimens (intravenous IV, subsothic injection SC). the induction period, patients were randomly divided into 4 treatment groups and treated with a placebo or 3 doses
-
Science Sub-Journal: Reveals that IL-21 played a key role in the immune response to neurological viral infections.
Time of Update: 2020-10-23
system. this finding supports further exploration of the use of IL-21 as a therapeutic agent to treat persistent central nervous system infections. study was recently published in the journal Science Immunology under the title "IL-21
-
Lilly and Johnson and Johnson announce the latest clinical results of IL-23 inhibitors for Crohn's disease!
Time of Update: 2020-10-19
and effectiveness of multiple dosage regimens and two dosing regimens (intravenous IV, subsothic injection SC). the induction period, patients were randomly divided into 4 treatment groups and treated with a placebo or 3 doses of mirikizumab (200 mg, 600 mg
-
Junshi Bio intends to introduce IL-2 series of products for US$88 million.
Time of Update: 2020-10-16
On September 30, Regency Bio announced that it intends to enter into a licensing agreement with Anwita Biosciences, which will grant Regency Bio the sole use of the Anti-HSA-IL-2N alpha series in the licensed area. this purpose, Regency
-
J Allergy Clin Immunol: Patients with high IL-17 asthma have psoriasis immunotypes.
Time of Update: 2020-10-12
an in-depth esologic study of asthma patients with il-17 immunity, was published online at J Allergy Clin Immunol. A genome-wide transcription group analysis was performed using skin brush tablets, bronchial biopsy specimens (91 asthma patients
-
Sansheng Jian anti-IL-4R alpha monoantial clinical trial was approved by NMPA.
Time of Update: 2020-10-12
611 can alleviate diseases such as endexual dermatitis by inhibiting IL-4R alpha and blocking signaling of IL-4 and IL-13.
